Budgetary Impact of Treatment with Adjuvant Imatinib for 1 Year Following Surgical Resection of Kit-Positive Localized Gastrointestinal Stromal Tumors

BACKGROUND: Imatinib mesylate, an orally administered kinase inhibitor that targets the Kit (CD117) protein, currently has 10 approved indications including treatment of chronic myelogenous leukemia and metastatic gastrointestinal stromal tumors (GIST). Treatment with adjuvant imatinib following sur...

Descripción completa

Detalles Bibliográficos
Autores principales: Rubin, Jamie L., Taylor, Douglas C.A., Sanon, Myrlene, Coombs, John H., Bollu, Vamsi K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2010
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437645/
https://www.ncbi.nlm.nih.gov/pubmed/20726677
http://dx.doi.org/10.18553/jmcp.2010.16.7.482

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437645/
https://www.ncbi.nlm.nih.gov/pubmed/20726677
http://dx.doi.org/10.18553/jmcp.2010.16.7.482

Ejemplares similares